Study examines outcomes of screening mammography for age, breast density, hormone therapy – Woman ages 50 to 74 years who undergo biennial screenings have a similar risk of advanced-stage disease and a lower cumulative risk of false-positive results than those who get mammograms annually, according to a study that compared the benefits and harms of the frequency of screening mammography to age, breast density and postmenopausal use of hormone therapy (HT).
Want to lose weight? Keep a food journal, don’t skip meals and avoid going out to lunch – Women who want to lose weight should faithfully keep a food journal, and avoid skipping meals and eating in restaurants ? especially at lunch. A wide range of self-monitoring and diet-related behaviors and meal patterns impact weight change among overweight.
Exercise, even mild physical activity, may reduce breast cancer risk – A new analysis done by University of North Carolina at Chapel Hill researchers has found that physical activity ? either mild or intense and before or after menopause ? may reduce breast cancer risk, but substantial weight gain may negate these benefits. The findings indicate that women can reduce their breast cancer risk by exercising and maintaining their weight.
Study finds moderate weight loss reduces levels of sex hormones linked to breast cancer risk – Even a moderate amount of weight loss can significantly reduce levels of circulating estrogens that are associated with an increased risk of breast cancer, revealed by researchers at Fred Hutchinson Cancer Research Center.
Long-term Use of Estrogen Hormone Therapy Linked to Higher Risk for Breast Cancer – Long-term use of estrogen plus progesterone and estrogen-only hormone therapy is linked with a higher risk for developing breast cancer. Researchers found this breast cancer risk was 88 percent higher.
Novartis drug Afinitor? helps women with advanced breast cancer live significantly longer without their disease progressing – A pivotal Phase III study shows Afinitor (everolimus) tablets plus exemestane, a hormonal therapy, more than doubled the time women lived without tumor growth (progression-free survival; PFS) and significantly reduced the risk of cancer progression by 57% versus exemestane alone in patients with advanced breast cancer.